SCHEDULE: Perceptive Backs Astria-BioCryst Merger

Perceptive Advisors and its affiliates have entered into a voting agreement to support BioCryst Pharmaceuticals' acquisition of Astria Therapeutics.

Summary

• Perceptive Advisors LLC, Joseph Edelman, Perceptive Life Sciences Master Fund, Ltd., and Perceptive Xontogeny Venture Fund, L.P. are the reporting persons in this Schedule 13D amendment.
• Perceptive Advisors LLC and Joseph Edelman collectively beneficially own 6,485,420 shares of Astria Therapeutics, Inc. common stock, representing 11.5% of the class.
• Perceptive Life Sciences Master Fund, Ltd. beneficially owns 4,873,721 shares, accounting for 8.6% of the common stock.
• Perceptive Xontogeny Venture Fund, L.P. beneficially owns 1,611,699 shares, representing 2.9% of the common stock.
• On October 14, 2025, Perceptive Life Sciences Master Fund and Perceptive Xontogeny Venture Fund entered into a Voting and Support Agreement with BioCryst Pharmaceuticals, Inc.
• The agreement commits these funds to vote their respective shares of Astria Therapeutics common stock in favor of the adoption of the merger agreement with BioCryst and Axel Merger Sub, Inc.
• The funds also agreed, with certain exceptions, not to transfer their shares of common stock prior to the earlier of the merger's effective time or the termination of the merger agreement.
• They further consented to the treatment of their Series X Convertible Preferred Stock and Warrants as outlined in the Merger Agreement.

Sentiment

Score: 7

Explanation: The filing indicates strong support from a significant institutional investor, Perceptive Advisors, for the proposed merger of Astria Therapeutics with BioCryst Pharmaceuticals. This commitment to vote in favor of the merger and restrict share transfers suggests confidence in the transaction's value proposition and increases the likelihood of the deal closing.

Positives

• Significant shareholder Perceptive Advisors and its affiliates are supporting the proposed acquisition of Astria Therapeutics by BioCryst Pharmaceuticals, Inc.
• The voting agreement indicates a commitment from major investors to the merger's successful completion, potentially increasing deal certainty.

Risks

• The Voting Agreements will terminate if the Merger Agreement is amended to reduce the consideration to be received by holders of Astria Therapeutics common stock.
• The Voting Agreements will terminate if the Merger Agreement is terminated for any reason, meaning the proposed acquisition may not be completed.

Future Outlook

The future outlook is centered on the proposed acquisition of Astria Therapeutics by BioCryst Pharmaceuticals, Inc., contingent on shareholder approval and other closing conditions. The voting agreement from a major shareholder increases the likelihood of the merger's successful completion.

Industry Context

Mergers and acquisitions are a common strategic move in the biotechnology sector, often driven by portfolio expansion, pipeline consolidation, or market positioning. The support from a major institutional investor like Perceptive Advisors for this specific merger could signal confidence in the strategic rationale and potential synergies, potentially influencing other shareholders' decisions and the overall market perception of the deal.

Corporate Governance

Stakeholder Impact

• Shareholders: The voting agreement from a major investor signals confidence in the merger, potentially influencing other shareholders' decisions and increasing the likelihood of the merger's completion, which could lead to receiving the merger consideration.
• Astria Therapeutics: Increased certainty regarding the successful completion of the merger due to significant shareholder support.
• BioCryst Pharmaceuticals: Secured a commitment from a major Astria shareholder, reducing uncertainty around merger approval and facilitating the acquisition process.

Next Steps

• Shareholders of Astria Therapeutics, Inc. will need to vote on the adoption of the merger agreement.
• Completion of the proposed acquisition of Astria Therapeutics by BioCryst Pharmaceuticals, Inc. is pending.

Key Dates

Recommendation

The filing indicates strong support from a significant institutional investor for the proposed merger. This increases the likelihood of the merger closing, suggesting that current shareholders might hold their shares to receive the merger consideration. Without details on the merger terms (e.g., cash vs. stock, premium), a definitive buy or sell recommendation is difficult, but the support reduces merger-related uncertainty.

Keywords

Astria Therapeutics, BioCryst Pharmaceuticals, Merger, Acquisition, Schedule 13D, Voting Agreement, Perceptive Advisors, Common Stock, Shareholder Support